CIK 0001326190 · Non-accelerated filer<br>Smaller reporting company
Altimmune, Inc.
Sign in to watch- Ticker
- ALT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 202726770
- Phone
- 862-457-1450
- Business address
- 350 MOUNT KEMBLE AVENUE, SUITE 1001, MORRISTOWN, NJ, 07960
- Former names
- PHARMATHENE, INC, HEALTHCARE ACQUISITION CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-02-13 | Novartis Bioventures Ltd 10% owner | Other acquisition | +269,527 | 2,804,088 | ||
| 2018-02-13 | Novartis Bioventures Ltd 10% owner | Other disposition · Series B Convertible Preferred Stock | −344.94 | 1,724.69 | ||
| 2018-01-17 | Novartis Bioventures Ltd 10% owner | Other acquisition | +176,586 | 2,534,561 | ||
| 2018-01-17 | Novartis Bioventures Ltd 10% owner | Other disposition · Series B Convertible Preferred Stock | −344.94 | 2,069.63 | ||
| 2018-01-17 | Truffle Capital S.A.S. 10% owner | Other acquisition | +11,655 | 157,155 | ||
| 2018-01-17 | Truffle Capital S.A.S. 10% owner | Other acquisition | +15,541 | 109,488 | ||
| 2018-01-17 | Truffle Capital S.A.S. 10% owner | Other acquisition | +11,655 | 54,428 | ||
| 2018-01-17 | Truffle Capital S.A.S. 10% owner | Other disposition · Series B Convertible Preferred Stock | −22.77 | 136.6 | ||
| 2018-01-17 | Truffle Capital S.A.S. 10% owner | Other disposition · Series B Convertible Preferred Stock | −30.35 | 182.13 | ||
| 2018-01-17 | Truffle Capital S.A.S. 10% owner | Other disposition · Series B Convertible Preferred Stock | −22.77 | 136.6 | ||
| 2018-01-02 | Enright William President and CEO | Option exercise | +183,347 | $0.08 | $15K | 364,511 |
| 2018-01-02 | Enright William President and CEO | Option exercise · Stock Options (option to buy) | −183,347 | 0 | ||
| 2017-12-29 | SAYARE MITCHEL Director | Purchase | +5,100 | $1.95 | $10K | 32,650 |
| 2017-12-29 | SCHAFFER DERACE L Director | Purchase | +38,699 | $1.93 | $75K | 589,453 |
| 2017-12-28 | SCHAFFER DERACE L Director | Purchase | +58,711 | $1.92 | $113K | 550,754 |
| 2017-12-27 | SCHAFFER DERACE L Director | Purchase | +50,000 | $1.76 | $88K | 464,337 |
| 2017-12-27 | SCHAFFER DERACE L Director | Purchase | +27,706 | $1.77 | $49K | 492,043 |
| 2017-12-26 | SCHAFFER DERACE L Director | Purchase | +51,442 | $1.81 | $93K | 414,337 |
| 2017-12-22 | SCHAFFER DERACE L Director | Purchase | +17,982 | $1.61 | $29K | 362,895 |
| 2017-12-15 | Truffle Capital S.A.S. 10% owner | Other acquisition | +4,337 | 145,500 |
Page 27 of 29 · 568 trades